INT24910

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1988
Last Reported 2010
Negated 0
Speculated 2
Reported most in Abstract
Documents 20
Total Number 22
Disease Relevance 8.23
Pain Relevance 4.67

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (Enpp3)
Anatomy Link Frequency
heart 3
neuronal 1
lung 1
neuromuscular junction 1
Enpp3 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
anesthesia 12 100.00 Very High Very High Very High
adenocard 8 99.80 Very High Very High Very High
Restless leg syndrome 33 99.36 Very High Very High Very High
Catecholamine 1 98.48 Very High Very High Very High
Spinal cord 5 98.20 Very High Very High Very High
Pain 15 97.76 Very High Very High Very High
potassium channel 1 95.80 Very High Very High Very High
intrathecal 1 95.36 Very High Very High Very High
cva 17 95.12 Very High Very High Very High
Hyperalgesia 3 90.36 High High
Disease Link Frequency Relevance Heat
Adult Respiratory Distress Syndrome 16 99.40 Very High Very High Very High
Increased Venous Pressure Under Development 50 99.36 Very High Very High Very High
Heart Rate Under Development 22 99.04 Very High Very High Very High
Myocardial Infarction 8 98.80 Very High Very High Very High
Hypothermia 11 98.36 Very High Very High Very High
Pain 13 97.76 Very High Very High Very High
Coronary Heart Disease 2 97.60 Very High Very High Very High
Peripheral Arterial Disease 16 95.96 Very High Very High Very High
Cv General 3 Under Development 11 95.12 Very High Very High Very High
Nicotine Addiction 6 94.56 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Topical application of amrinone (a selective phosphodiesterase III inhibitor) for relief of vasospasm.
Negative_regulation (inhibitor) of phosphodiesterase III associated with increased venous pressure under development
1) Confidence 0.57 Published 2000 Journal J. Surg. Res. Section Title Doc Link 10945957 Disease Relevance 0.27 Pain Relevance 0.08
The results suggest that MCI-154 is a potent cardiotonic agent, and that inhibition of phosphodiesterase III may be a important component of this effect.
Negative_regulation (inhibition) of phosphodiesterase III
2) Confidence 0.52 Published 1988 Journal Arzneimittelforschung Section Abstract Doc Link 2854467 Disease Relevance 0.09 Pain Relevance 0
The drug inhibited selectively canine cardiac phosphodiesterase III (IC50 2.5 +/- 0.6 mumol/l).
Negative_regulation (inhibited) of phosphodiesterase III
3) Confidence 0.46 Published 1988 Journal Arzneimittelforschung Section Abstract Doc Link 2854467 Disease Relevance 0.10 Pain Relevance 0
Inhibition of cardiac phosphodiesterase III by the novel cardiotonic agent 6-[4-(4'-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride.
Negative_regulation (Inhibition) of phosphodiesterase III associated with anesthesia
4) Confidence 0.46 Published 1988 Journal Arzneimittelforschung Section Title Doc Link 2854467 Disease Relevance 0.08 Pain Relevance 0.10
In addition to sensitizing troponin to intracellular calcium, levosimendan has been shown to inhibit phosphodiesterase III, which may contribute to its positive inotropic effect, and open adenosine triphosphate (ATP)-sensitive potassium channels (K(ATP)), which may produce vasodilation.
Negative_regulation (inhibit) of phosphodiesterase III associated with adenocard, potassium channel and increased venous pressure under development
5) Confidence 0.42 Published 2002 Journal Heart Dis Section Abstract Doc Link 12147186 Disease Relevance 0.27 Pain Relevance 0.10
BACKGROUND: Amrinone, a selective phosphodiesterase III inhibitor, is an agent that possesses a combination of positive inotropic and vasodilating properties as a result of preventing the degradation of cAMP, and it has recently been licensed for the treatment of heart failure.
Negative_regulation (inhibitor) of phosphodiesterase III in heart associated with myocardial infarction
6) Confidence 0.41 Published 2000 Journal J. Surg. Res. Section Abstract Doc Link 10945957 Disease Relevance 0.24 Pain Relevance 0.07
BACKGROUND: Cilostazol, a phosphodiesterase III inhibitor, is indicated to treat the symptoms of intermittent claudication and increase walking distance in patients with peripheral arterial disease (PAD).
Negative_regulation (inhibitor) of phosphodiesterase III associated with restless leg syndrome and peripheral arterial disease
7) Confidence 0.40 Published 2008 Journal J. Vasc. Surg. Section Abstract Doc Link 18155871 Disease Relevance 0.36 Pain Relevance 0.10
Cilostazol, a phosphodiesterase III inhibitor, appears to provide the greatest benefit, significantly improving not only walking distance but quality of life as well.
Negative_regulation (inhibitor) of phosphodiesterase III
8) Confidence 0.40 Published 2002 Journal Vasc Med Section Abstract Doc Link 12710846 Disease Relevance 0.55 Pain Relevance 0.36
OBJECTIVES: To assess whether cilostazol, a phosphodiesterase III inhibitor, improves treadmill and community-based walking ability and health-related quality of life (HQL) in patients with intermittent claudication resulting from peripheral arterial disease (PAD).
Spec (whether) Negative_regulation (inhibitor) of phosphodiesterase III associated with restless leg syndrome and peripheral arterial disease
9) Confidence 0.40 Published 2002 Journal J Am Geriatr Soc Section Abstract Doc Link 12473004 Disease Relevance 0.43 Pain Relevance 0.17
Cilostazol is a phosphodiesterase III inhibitor with antiplatelet, antithrombotic and vasodilatory effects.
Negative_regulation (inhibitor) of phosphodiesterase III
10) Confidence 0.40 Published 2001 Journal Int J Clin Pract Suppl Section Abstract Doc Link 11355274 Disease Relevance 0.20 Pain Relevance 0.20
Milrinone, a phosphodiesterase III inhibitor, prevents degradation of cyclic adenosine monophosphate in cardiac myocytes to increase contractile force of the heart muscle, and it relaxes the vascular smooth muscle to reduce systemic vascular resistance [8].
Negative_regulation (inhibitor) of phosphodiesterase III in heart associated with adenocard
11) Confidence 0.31 Published 2010 Journal Korean Journal of Anesthesiology Section Body Doc Link PMC2926436 Disease Relevance 0.23 Pain Relevance 0.05
Vasodilators have a purely symptomatic effect, modest at best, in increasing walking distance; (2) Cilostazol, a phosphodiesterase III inhibitor, is licensed in France (after 20 years on the market in Japan) as a treatment intended to increase walking distance in patients with intermittent claudication; (3) A double-blind placebo-controlled trial in 1439 patients showed no reduction in mortality after 3 years of treatment; (4) Cilostazol has been compared with pentoxifylline, another vasodilator with uncertain efficacy, in 3 clinical trials.
Negative_regulation (inhibitor) of phosphodiesterase III associated with restless leg syndrome
12) Confidence 0.29 Published 2009 Journal Prescrire Int Section Abstract Doc Link 19585717 Disease Relevance 0.49 Pain Relevance 0.31
However, excess mortality has been documented with other phosphodiesterase III inhibitors, especially in patients with heart failure; (7) Cilostazol can provoke dose-dependent cardiac arrhythmias, and sometimes haemorrhage (due to its antiplatelet effect); (8) Cilostazol is extensively metabolised by cytochrome P450 isoenzymes CYP 3A4 and CYP 2C6, creating a high risk of pharmacokinetic interactions with other drugs and with food; (9) In practice, patients with intermittent claudication should not be given cilostazol; they should instead be prescribed an antiplatelet drug and encouraged to stop smoking and to exercise regularly.
Negative_regulation (inhibitors) of phosphodiesterase III in heart associated with nicotine addiction, restless leg syndrome, cva and myocardial infarction
13) Confidence 0.29 Published 2009 Journal Prescrire Int Section Abstract Doc Link 19585717 Disease Relevance 0.76 Pain Relevance 0.42
Does phosphodiesterase III inhibition reverse the cardiodepressive effects of propofol?
Negative_regulation (inhibition) of phosphodiesterase III
14) Confidence 0.29 Published 1997 Journal Anesth. Analg. Section Title Doc Link 9322446 Disease Relevance 0.27 Pain Relevance 0.07
The present study showed that cyclic guanosine monophosphate-dependent protein kinase Ialpha but not Ibeta was localized in the neuronal bodies and processes, and was distributed primarily in the superficial laminae of the spinal cord.
Negative_regulation (distributed) of Ibeta in neuronal associated with spinal cord
15) Confidence 0.07 Published 2000 Journal Neuroscience Section Abstract Doc Link 10658633 Disease Relevance 0.34 Pain Relevance 0.62
Cilostazol is a phosphodiesterase type 3 inhibitor.
Negative_regulation (inhibitor) of phosphodiesterase type 3
16) Confidence 0.04 Published 2001 Journal Cardiol Rev Section Abstract Doc Link 11405904 Disease Relevance 0.98 Pain Relevance 0.19
It acts primarily through selective inhibition of phosphodiesterase III (PDE-III) and has additional vasodilating properties.
Negative_regulation (inhibition) of phosphodiesterase III
17) Confidence 0.03 Published 1989 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 2480486 Disease Relevance 0.05 Pain Relevance 0.13
AIM: Cilostazol is a phosphodiesterase III inhibitor with a firm evidence base for use in intermittent claudication.
Negative_regulation (inhibitor) of phosphodiesterase III associated with restless leg syndrome
18) Confidence 0.02 Published 2009 Journal Int Angiol Section Abstract Doc Link 19935589 Disease Relevance 0.17 Pain Relevance 0.18
Milrinone, a phosphodiesterase III inhibitor, is supposed to increase the release of acetylcholine at the neuromuscular junction and make the neuromuscular junction sensitive to acetylcholine.
Negative_regulation (inhibitor) of phosphodiesterase III in neuromuscular junction
19) Confidence 0.01 Published 2005 Journal J Anesth Section Abstract Doc Link 16261467 Disease Relevance 0.17 Pain Relevance 0.10
In another study, Bueltmann et al. [63] examined the effects of inhaled milrinone, a phosphodiesterase 3 inhibitor, in models of acute lung injury following infusion of oleic acid in rats or intratracheal instillation of hydrochloric acid in mice.
Spec (examined) Negative_regulation (inhibitor) of phosphodiesterase 3 in lung associated with adult respiratory distress syndrome
20) Confidence 0.01 Published 2010 Journal Intensive Care Med Section Body Doc Link PMC2820226 Disease Relevance 0.72 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox